New ultrasound device could spot liver disease early and speed up specialist care
NCT ID NCT06387745
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new, non-invasive ultrasound device called the Hepatoscope to screen for liver scarring (fibrosis) and fatty liver in people at risk. Researchers will enroll 200 patients with risk factors like diabetes or elevated liver enzymes. Those with high stiffness readings on the scan will be referred to a liver specialist, and the device's accuracy will be compared to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hepatoscope (non-invasive ultrasound device)
What this could lead to
If successful, this could provide a simple, non-invasive way to identify patients who need specialist care for chronic liver disease, potentially catching problems earlier.
What could go wrong
This is an early-stage diagnostic study with 200 participants, so results may not apply to everyone. The device's accuracy compared to standard tests is still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universitair Ziekenhuis Antwerpen
RECRUITINGEdegem, Antwerp, 2650, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••